Recent research published in Endocrine journal highlighted the need for integrating sexual health into diabetes care, as female sexual dysfunction (FSD) is a common complication in T2DM patients.

The study aimed to examine the incidence, prevalence, and remission of FDS in women who were newly diagnosed with uncomplicated T2DM and to identify the associated factors.

From newly diagnosed T2DM patients (n=937), researchers enrolled 388 women. A Female Sexual Function Index (FSFI) score of less than 26.55 was considered FSD. Evaluation of parameters, including metabolic, therapeutic (including therapeutic patient education (TPE)), and anthropometric, was done at baseline and during the follow-up period. The predictors of FSD incidence, prevalence, and remission were identified using multivariate logistic regression.

Results revealed that the prevalence rate of FSD at baseline was 42.8%, of whom 28.9% had remission. 30.2% of initially unaffected women developed FSD during the follow-up. An independent association was observed with baseline FSD and BMI > 30 kg/m², age > 50 years.

TPE and total testosterone > 28.5 ng/dL increased FSD prevalence. The participation in TPE and a BMI reduction of more than 3 points showed a recovery from FSD.